BNP Paribas Financial Markets
KBIO

BNP Paribas Financial Markets’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

BNP Paribas Financial Markets’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-19
Closed -$681 – 4298
2013
Q4 		$681 Buy
+19
New +$637 ﹤0.01% 3901

Other funds holding KBIO

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BNP Paribas Financial Markets's KBIO Position: Q1 2014 in Review

BNP Paribas Financial Markets sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q1 2014, closing a stake of 19 shares — an estimated $681 sold.

BNP Paribas Financial Markets first reported a position in KBIO in Q4 2013 and held it in 1 quarter. The position peaked at $681 in Q4 2013. 48 funds tracked by Wall St. Rank hold KBIO as of Q1 2014.

  • BNP Paribas Financial Markets reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q1 2014 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 19 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q1 2014, an estimated $681.
  • BNP Paribas Financial Markets first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q4 2013 and held it in 1 quarter.
  • BNP Paribas Financial Markets's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $681 in Q4 2013.
  • 48 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q1 2014.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2014, filed 13 May 2014.